Rehab Clinic Busted by DEA for Sloppy Narcotics Paperwork
Published Date: 10/2/2025
Notice
Summary
Hollywood Medical Rehabilitation Care, Inc. lost its DEA registration because it didn’t keep proper records for narcotic treatments. The company missed important deadlines to respond, so the government shut down its license starting December 2024. This means they can’t legally handle controlled substances anymore, affecting their business and patients relying on their care.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Revokes Clinic's Controlled‑Substance License
If you are a patient of Hollywood Medical Rehabilitation Care in Los Angeles, the DEA revoked its Certificate of Registration No. RH0554053. The revocation is effective November 3, 2025, and means the clinic may no longer legally possess, dispense, or handle controlled substances.
Clinic's Registration Revoked; Renewals Denied
Hollywood Medical Rehabilitation Care, Inc. had DEA Certificate of Registration No. RH0554053 revoked and the DEA denied any pending renewal, modification, or other registration applications for the company in California. The Order is effective November 3, 2025, preventing the business from legally operating with controlled substances.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-19379, Government Owned Inventions Available for Licensing and/or Collaboration: Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology
The National Cancer Institute has a cool new gadget that uses sound waves to tag and sort cells automatically. They’re looking for partners or companies to help bring this tech to life and make it available for research and medical use. This is a great chance to team up with the government and speed up important health discoveries!
Next: 2025-19380, Notice Pursuant to the National Cooperative Research and Production Act of 1993-The Open Group, L.L.C.
The Open Group just updated its membership with new companies and universities from around the world, including places like Hungary, Australia, and the U.S. This change keeps special legal protections in place that limit antitrust lawsuit damages to actual losses. These updates were officially filed on August 22, 2025, and affect all members involved in this tech and research collaboration.